Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target
Trade with 70% Backtested Accuracy
Analyst Views on IBIO
About IBIO
About the author
iBio Reports Q2 Financials with Increased Losses
- Earnings Report Loss: iBio's Q2 GAAP EPS stands at -$0.09, indicating ongoing challenges in profitability that may undermine investor confidence and exert downward pressure on the stock price.
- Cash Reserves: As of December 31, 2025, iBio reported cash, cash equivalents, and investments in debt securities totaling $52.7 million, ensuring operational funding for the coming years.
- Financing Activity: In January 2026, the company secured approximately $24.4 million in net proceeds from PIPE financing, extending its cash runway into the third quarter of fiscal year 2028, thereby enhancing its financial stability.
- Private Placement Plans: iBio announced a private placement financing plan to raise approximately $26 million, aimed at further strengthening its capital structure and supporting future R&D and operational needs.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
iBio Reveals Promising Non-Human Primate Data for IBIO-610, an Activin E Antibody with Significant Potential for Targeted Weight Loss and Maintenance
IBIO-610 Overview: iBio, Inc. has announced promising preclinical data for IBIO-610, a potential first-in-class Activin E antibody, showing significant fat-selective weight loss and prevention of weight regain in a diet-induced obesity mouse model.
Extended Half-Life Findings: New data from non-human primate studies indicates an extended half-life of 33.2 days, with a predicted human half-life of up to 100 days, suggesting the possibility of dosing only twice a year.
Therapeutic Potential: The unique mechanism of action of IBIO-610 may provide a more comprehensive treatment for obesity and cardiometabolic diseases, addressing gaps left by current GLP-1 therapies.
Presentation at ObesityWeek: The findings will be presented at ObesityWeek 2025, highlighting the potential of IBIO-610 to improve patient experience with less frequent dosing and reduced side effects compared to existing treatments.
iBio to Attend the 2nd Annual Healthcare Innovation Conference Hosted by Guggenheim
iBio's Conference Participation: iBio, Inc. will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference from November 10–12, 2025, where CEO Martin Brenner will discuss the company's advancements in becoming a clinical-stage biotechnology firm and its obesity pipeline.
Focus on Obesity Treatments: During the conference, Dr. Brenner will highlight iBio's differentiated antibody programs aimed at complementing existing obesity therapies and creating long-term value through innovation.
One-on-One Meetings: CFO Felipe Duran will join Dr. Brenner for one-on-one meetings with attendees at the conference, providing further insights into the company's strategies and developments.
Company Overview: iBio is a biotech company utilizing AI and advanced computational biology to develop innovative biopharmaceuticals for various diseases, including obesity and cancer, with a mission to transform drug discovery and accelerate development timelines.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
iBio to Showcase New Preclinical Findings on Its Activin E Antibody at ObesityWeek® and PEGS Europe 2025 Conferences
iBio Presentations: iBio, Inc. will present research on its Activin E antibody, IBIO-610, at ObesityWeek 2025 and PEGS Europe 2025, highlighting its potential for treating obesity and enhancing current therapies.
Research Findings: The data from non-human primate studies suggest that IBIO-610 may enable fat-selective weight loss, support long-term weight maintenance, and improve the efficacy of GLP-1 therapies.
Presentation Details: Cory Schwartz will present on November 4, 2025, at ObesityWeek, while Martin Brenner will present on November 12, 2025, at PEGS Europe, discussing the innovative approaches to obesity treatment.
Company Overview: iBio is a biotech firm focused on developing advanced biopharmaceuticals for cardiometabolic diseases, utilizing AI and computational biology to create breakthrough antibody treatments.
iBio Reports Q2 Financials with Increased Losses
- Earnings Report Loss: iBio's Q2 GAAP EPS stands at -$0.09, indicating ongoing challenges in profitability that may undermine investor confidence and exert downward pressure on the stock price.
- Cash Reserves: As of December 31, 2025, iBio reported cash, cash equivalents, and investments in debt securities totaling $52.7 million, ensuring operational funding for the coming years.
- Financing Activity: In January 2026, the company secured approximately $24.4 million in net proceeds from PIPE financing, extending its cash runway into the third quarter of fiscal year 2028, thereby enhancing its financial stability.
- Private Placement Plans: iBio announced a private placement financing plan to raise approximately $26 million, aimed at further strengthening its capital structure and supporting future R&D and operational needs.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
iBio Reveals Promising Non-Human Primate Data for IBIO-610, an Activin E Antibody with Significant Potential for Targeted Weight Loss and Maintenance
IBIO-610 Overview: iBio, Inc. has announced promising preclinical data for IBIO-610, a potential first-in-class Activin E antibody, showing significant fat-selective weight loss and prevention of weight regain in a diet-induced obesity mouse model.
Extended Half-Life Findings: New data from non-human primate studies indicates an extended half-life of 33.2 days, with a predicted human half-life of up to 100 days, suggesting the possibility of dosing only twice a year.
Therapeutic Potential: The unique mechanism of action of IBIO-610 may provide a more comprehensive treatment for obesity and cardiometabolic diseases, addressing gaps left by current GLP-1 therapies.
Presentation at ObesityWeek: The findings will be presented at ObesityWeek 2025, highlighting the potential of IBIO-610 to improve patient experience with less frequent dosing and reduced side effects compared to existing treatments.
iBio to Attend the 2nd Annual Healthcare Innovation Conference Hosted by Guggenheim
iBio's Conference Participation: iBio, Inc. will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference from November 10–12, 2025, where CEO Martin Brenner will discuss the company's advancements in becoming a clinical-stage biotechnology firm and its obesity pipeline.
Focus on Obesity Treatments: During the conference, Dr. Brenner will highlight iBio's differentiated antibody programs aimed at complementing existing obesity therapies and creating long-term value through innovation.
One-on-One Meetings: CFO Felipe Duran will join Dr. Brenner for one-on-one meetings with attendees at the conference, providing further insights into the company's strategies and developments.
Company Overview: iBio is a biotech company utilizing AI and advanced computational biology to develop innovative biopharmaceuticals for various diseases, including obesity and cancer, with a mission to transform drug discovery and accelerate development timelines.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
iBio to Showcase New Preclinical Findings on Its Activin E Antibody at ObesityWeek® and PEGS Europe 2025 Conferences
iBio Presentations: iBio, Inc. will present research on its Activin E antibody, IBIO-610, at ObesityWeek 2025 and PEGS Europe 2025, highlighting its potential for treating obesity and enhancing current therapies.
Research Findings: The data from non-human primate studies suggest that IBIO-610 may enable fat-selective weight loss, support long-term weight maintenance, and improve the efficacy of GLP-1 therapies.
Presentation Details: Cory Schwartz will present on November 4, 2025, at ObesityWeek, while Martin Brenner will present on November 12, 2025, at PEGS Europe, discussing the innovative approaches to obesity treatment.
Company Overview: iBio is a biotech firm focused on developing advanced biopharmaceuticals for cardiometabolic diseases, utilizing AI and computational biology to create breakthrough antibody treatments.
